|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
18.38 Million
|
|
CAGR
(2024-2029)
|
6.54%
|
|
Fastest
Growing Segment
|
Smallpox
Vaccine
|
|
Largest
Market
|
London
|
|
Market
Size (2029)
|
USD
26.58 Million
|
Market Overview
United
Kingdom Monkeypox Therapeutics Market was valued at USD 18.38 Million in 2023 and
is expected to reach USD 26.58 Million by 2029 with a CAGR of 6.54% during the
forecast period. The United Kingdom (UK) Monkeypox therapeutics market is
witnessing significant developments as the country navigates the challenges
posed by the emerging and re-emerging Monkeypox outbreaks. This market is
shaped by a combination of factors including regulatory actions, public health
strategies, and the increasing demand for effective therapeutic solutions. As
the UK grapples with Monkeypox, understanding the dynamics of its therapeutics
market is crucial for stakeholders including healthcare providers,
pharmaceutical companies, and policymakers.
The
recent increase in Monkeypox cases, particularly in non-endemic regions, has
heightened the focus on developing and deploying effective therapeutics. The UK
has experienced sporadic outbreaks, which have amplified the demand for
targeted interventions and treatments to manage and prevent the disease.
The
UK government has played a pivotal role in shaping the Monkeypox therapeutics
market through various initiatives. This includes funding for research and
development (R&D) aimed at advancing the discovery and production of
Monkeypox-specific treatments and vaccines. Agencies such as the Department of
Health and Social Care (DHSC) and Public Health England (PHE) are actively
involved in supporting these efforts.
Despite
positive developments, the UK Monkeypox therapeutics market faces several
challenges. One significant issue is the limited availability of approved treatments
and vaccines. The supply of these therapeutics is constrained by production
capacity and distribution logistics. Additionally, the cost of R&D and the
regulatory hurdles associated with new drug approvals can impact the pace at
which new solutions become available.
Furthermore,
ensuring equitable access to therapeutics across different regions, including
remote and underserved areas, remains a challenge. Addressing these issues is
critical to achieving comprehensive disease management and preventing
outbreaks.
Key Market Drivers
Increasing Incidence of
Monkeypox Cases
Recent
years have witnessed a notable uptick in Monkeypox cases both globally and
within the UK. The disease, characterized by its symptoms similar to those of smallpox,
has expanded beyond its traditional geographic boundaries, impacting new
regions and demographics. In response, the UK has seen a heightened focus on
addressing the threat posed by Monkeypox through the development and deployment
of targeted therapeutics.
The
growing number of Monkeypox cases has driven significant market activity. As
outbreaks become more frequent and widespread, there is a heightened demand for
effective antiviral drugs and vaccines. This increased demand is propelling
growth in the Monkeypox therapeutics market, as healthcare providers and
pharmaceutical companies work to develop and deliver solutions that can manage
and mitigate the impact of the disease.
According
to a report published by gov.uk in 2024, mpox cases acquired within the UK have
been confirmed in England since May 6, 2022. The outbreak has predominantly
affected gay, bisexual, and other men who have sex with men, without a
documented history of travel to endemic regions. Positive samples identified by
a mpox polymerase chain reaction (PCR) test are classified as confirmed cases,
while samples positive for an orthopox PCR test, which includes mpox, are
classified as highly probable cases. The reported figures combine both
classifications.
As
of December 31, 2022, there were 3,732 confirmed and highly probable mpox cases
in the UK, with 3,553 cases in England, 34 in Northern Ireland, 97 in Scotland,
and 48 in Wales. In 2023 and up to July 31, 2024, a total of 286 mpox cases
have been reported in the UK. Of these, 269 were in England (116 cases were
presumed to have been acquired within the UK, 82 were acquired abroad, and 71
are pending classification), 11 were in Scotland (7 were imported cases, 3 were
presumed to have been acquired in the UK, and 1 is pending classification), 1
was in Wales (an imported case acquired outside the UK), and 5 were in Northern
Ireland (1 was presumed to have been acquired in the UK, 1 was an imported
case, and 3 are pending classification).
The
UK government has been proactive in addressing the challenges posed by the
increasing incidence of Monkeypox. Key initiatives include the acceleration of
regulatory processes for the approval of therapeutics and vaccines. The
Medicines and Healthcare products Regulatory Agency (MHRA) has streamlined
approval pathways for drugs and vaccines, including those repurposed from
smallpox treatments, to ensure that effective solutions are available promptly.
Additionally,
the government has invested in research and development (R&D) to advance
the discovery and production of Monkeypox-specific therapeutics. Funding from
public health bodies such as the Department of Health and Social Care (DHSC)
has been directed towards enhancing the R&D pipeline, fostering innovation,
and supporting the development of new treatment modalities.
As
Monkeypox cases rise, public awareness campaigns and vaccination programs are
being intensified. Health authorities are focusing on educating the public
about the disease and the availability of preventive measures. These efforts are
driving demand for vaccines and therapeutics, thereby fueling market growth.
The
UK government has established stockpiles of smallpox vaccines and antiviral
medications to ensure rapid response during outbreaks. This strategic
preparedness is vital for managing increased case numbers and has a direct
impact on the therapeutics market by ensuring that critical resources are
readily available.
The
rising incidence of Monkeypox has spurred increased investment in R&D aimed
at developing new therapeutics and optimizing existing ones. Pharmaceutical
companies are focusing on advancing drug formulations and improving vaccine
efficacy, which is contributing to market expansion.
Advances in Therapeutic
Research
The
rapid progression in research and development (R&D) is at the forefront of
driving the monkeypox therapeutics market in the UK. The nation’s robust
scientific infrastructure, comprising leading pharmaceutical companies,
research institutions, and academic bodies, is instrumental in pushing the boundaries
of therapeutic innovation. Researchers are focusing on developing novel
antivirals, vaccines, and monoclonal antibodies tailored to combat monkeypox
effectively.
In
March 2024, a new mpox vaccine is undergoing trials in the UK as the virus
persists globally. The mPower trial, conducted by the NIHR Clinical Research
Network (CRN) and sponsored by Moderna, is evaluating the effectiveness of an
investigational mRNA vaccine for mpox. Since 2022, there has been a notable
increase in mpox transmission within the UK. Common symptoms of mpox include a
rash with painful blisters, fever, chills, muscle aches, swollen lymph nodes,
and a sore throat.
Advanced
research methodologies, such as high-throughput screening, genomic analysis,
and computational modeling, are enhancing the discovery and optimization of new
therapeutic candidates. These technologies allow for a more efficient
identification of potential treatments and accelerate the progression from
preclinical studies to clinical trials. As a result, the therapeutic pipeline
for monkeypox is expanding, with promising candidates moving closer to market
availability.
The
advancement of monkeypox therapeutics in the UK is significantly driven by
collaborative efforts and strategic partnerships. Pharmaceutical companies,
academic institutions, and public health organizations are working together to
accelerate research and development. These partnerships facilitate the sharing
of knowledge, resources, and data, leading to more rapid and effective
therapeutic innovations.
For
example, collaborations between UK-based pharmaceutical firms and global health
organizations have led to the development of cutting-edge vaccines and
antiviral treatments. These partnerships also help streamline the clinical
trial process, enabling the rapid testing and approval of new therapeutics.
The
UK’s regulatory framework supports and accelerates the development of new
therapeutics through streamlined approval processes. The Medicines and
Healthcare products Regulatory Agency (MHRA) plays a crucial role in expediting
the review and approval of monkeypox treatments. The agency’s commitment to
regulatory agility ensures that promising therapeutics are assessed
efficiently, allowing for quicker market entry.
Clinical
trials conducted in the UK are critical for validating the efficacy and safety
of new treatments. The country’s advanced clinical research infrastructure,
including specialized research centers and trial networks, supports the
rigorous testing of therapeutic candidates. Successful trials not only advance
the development of new treatments but also enhance the market’s growth
potential.
Download Free Sample Report
Key Market Challenges
Economic and Budgetary
Constraints
The
development of new therapeutics for Monkeypox requires substantial financial
investment in research and development (R&D). Pharmaceutical companies and
research institutions face high costs associated with clinical trials,
regulatory approvals, and manufacturing processes. In a market with relatively
low incidence rates compared to other infectious diseases, the return on
investment for developing Monkeypox therapeutics may appear limited. This
economic reality can deter companies from investing heavily in R&D for new
treatments. As a result, the market may experience a shortage of innovative
therapeutic options, hindering the UK's ability to address Monkeypox outbreaks
comprehensively.
The
allocation of funds to public health programs in the UK is influenced by
broader economic conditions and government budgetary priorities. In times of
economic uncertainty or financial constraints, public health budgets may face
cuts or reallocations. This can impact funding available for purchasing and
stockpiling Monkeypox therapeutics, as well as for implementing prevention and
treatment programs. Budget constraints can lead to reduced availability of
essential medicines and limit the resources allocated to managing outbreaks
effectively. Ensuring that adequate funding is available for Monkeypox
therapeutics amidst competing public health needs is a critical challenge for
policymakers.
Economic
constraints can also affect the procurement and distribution of Monkeypox
therapeutics. The costs associated with acquiring and distributing therapeutics
can be significant, particularly when ensuring a supply chain that reaches
remote or underserved areas. Budget limitations may result in delays or
shortages in the availability of therapeutics, impacting the ability of
healthcare providers to manage and treat Monkeypox cases promptly. Efficient
procurement and distribution systems are essential for ensuring that
therapeutics are accessible where they are most needed, but financial
constraints can compromise these systems.
Funding
for research into Monkeypox therapeutics is crucial for advancing treatment
options and improving outcomes. However, economic constraints can limit the
availability of grants and subsidies for research institutions and
pharmaceutical companies. This lack of funding can slow the pace of innovation
and delay the development of new and more effective therapeutics. To overcome
this challenge, increased investment in research and strategic partnerships
between public and private sectors are necessary to support the development of
novel treatments and enhance the therapeutic landscape.
Key Market Trends
Public Awareness and Health
Campaigns
One
of the primary objectives of public awareness campaigns is to drive engagement
and educate the public about monkeypox. These campaigns aim to provide clear,
accurate, and accessible information regarding the nature of the disease, its
symptoms, transmission routes, and preventive measures. By leveraging various
media platforms, including television, social media, and print media, the UK
government and health organizations are working to reach a broad audience. The
focus on education helps demystify monkeypox, reduce stigma, and encourage
timely medical consultation and reporting.
A
significant component of the public awareness strategy is the promotion of vaccination
and adherence to therapeutic protocols. Campaigns are designed to highlight the
importance of vaccination in preventing monkeypox and to address any vaccine
hesitancy. By providing information on vaccine safety and efficacy, the UK aims
to increase vaccination rates and, consequently, reduce the incidence of
monkeypox. Similarly, public health messages emphasize the importance of
following prescribed therapeutic regimens to ensure optimal outcomes for those
affected by the disease.
Public
awareness campaigns are integral to the UK’s response strategy during monkeypox
outbreaks. Rapid dissemination of information helps to mobilize resources,
coordinate responses, and guide public behavior in crisis situations. During an
outbreak, timely updates on the spread of the disease, availability of
treatments, and preventive measures are essential. This approach not only
supports individual health but also aids in controlling the spread of the
virus, thereby reducing the overall burden on the healthcare system.
Misinformation
and stigma can significantly hinder public health efforts. The UK's health
campaigns are designed to counteract misinformation by providing evidence-based
information and clarifying misconceptions about monkeypox. Addressing stigma is
also a key focus, as negative perceptions can discourage individuals from
seeking medical help or participating in preventive measures. By promoting an
inclusive and factual narrative, these campaigns work to create a supportive
environment for affected individuals and enhance overall public health
engagement.
Segmental Insights
Treatment Insights
Based
on Treatment, Smallpox Vaccine have emerged as the fastest growing segment in
the United Kingdom Monkeypox Therapeutics Market in 2023. The smallpox vaccine,
originally developed to combat smallpox, has demonstrated significant efficacy
in providing cross-protection against Monkeypox. Both diseases are caused by
viruses within the Orthopoxvirus genus, which share genetic and antigenic
similarities. Consequently, the smallpox vaccine not only prevents smallpox but
also offers substantial protection against Monkeypox. This cross-protection has
been validated through studies and historical data, reinforcing the vaccine's
relevance in combating Monkeypox.
The
vaccine’s proven effectiveness has led to its rapid adoption as a preventive
measure in the UK. Given the rise in Monkeypox cases and the vaccine’s ability
to mitigate the disease, it has become a cornerstone of the UK's therapeutic
strategy, driving its prominence in the market.
Regulatory
agencies in the UK, including the Medicines and Healthcare products Regulatory
Agency (MHRA), have facilitated the rapid approval of smallpox vaccines for use
against Monkeypox. The streamlined regulatory processes and emergency use
authorizations have accelerated the availability of these vaccines, allowing
them to be quickly integrated into public health strategies.
This
regulatory support has been instrumental in the rapid growth of the smallpox
vaccine segment. By expediting the approval process, the UK has ensured that
effective preventive measures are readily accessible, thereby boosting market
growth and expanding the vaccine’s role in Monkeypox therapeutics.
End User Insights
Based
on End User, Hospitals have emerged as the fastest growing segment in the United
Kingdom Monkeypox Therapeutics Market during the forecast period. The surge in
monkeypox cases has significantly impacted the demand for effective
therapeutics and specialized medical care. Hospitals, as key healthcare
institutions, are at the forefront of managing and treating monkeypox cases.
The increasing incidence of the disease necessitates a robust healthcare
response, positioning hospitals as central players in the therapeutics market.
The
complexity and severity of monkeypox symptoms often require advanced medical
interventions that are best managed within hospital settings. Hospitals are
equipped with the necessary infrastructure, including isolation units,
intensive care facilities, and specialized medical staff, to provide
comprehensive care for patients. This growing demand for hospital-based
treatment drives the expansion of the therapeutics market within these
institutions.
Hospitals
are uniquely positioned to address the monkeypox outbreak due to their
specialized infrastructure and expertise. They offer a range of resources and
services essential for effective disease management, including diagnostic
testing, treatment administration, and patient monitoring. The ability of
hospitals to provide integrated care, including antiviral treatments and
supportive therapies, enhances their role in the monkeypox therapeutics market.
Additionally,
hospitals often serve as centers for clinical trials and research, contributing
to the development and evaluation of new treatments. Their capacity to conduct
rigorous clinical research accelerates the introduction of innovative
therapeutics and drives market growth. The specialized knowledge and
capabilities of hospital staff further support the effective use of these new
treatments.
Download Free Sample Report
Regional Insights
Based
on Region, London have emerged as the dominating region in the United Kingdom Monkeypox
Therapeutics Market in 2023. London boasts a highly developed healthcare
infrastructure that is pivotal in its dominance within the Monkeypox
Therapeutics Market. The city is home to world-renowned medical institutions,
such as the Royal Free Hospital and St. Thomas' Hospital, which are equipped
with cutting-edge facilities and expertise in infectious disease management.
These institutions play a crucial role in diagnosing, treating, and researching
Monkeypox, providing a strong foundation for the development and deployment of
therapeutics. The concentration of high-quality healthcare resources in London
facilitates rapid response to outbreaks and supports the effective management
of Monkeypox cases.
The
presence of prestigious research institutions and universities in London,
including Imperial College London and University College London, drives the
city’s prominence in the Monkeypox therapeutics sector. These institutions are
at the forefront of biomedical research and innovation, contributing to the
development of new therapeutic solutions for Monkeypox. The collaboration
between academic researchers and pharmaceutical companies in London fosters an
environment of innovation, leading to advancements in therapeutic options and
the acceleration of clinical trials. This research excellence enhances London’s
position as a leader in the Monkeypox Therapeutics Market.
London
benefits from significant support from government agencies and public health
organizations that are instrumental in addressing Monkeypox outbreaks. The
city’s role as the capital of the UK means it is a focal point for national
public health initiatives and emergency response strategies. Agencies such as
Public Health England and the Department of Health and Social Care are based in
London, providing coordinated efforts in managing Monkeypox outbreaks,
including the procurement and distribution of therapeutics. The strategic
location of these agencies ensures that London is at the center of
decision-making and resource allocation for therapeutic interventions.
Recent Development
- In
March 2024, the National Institute for Health and Care Research (NIHR)
announced the launch of a new vaccine trial for mpox (formerly monkeypox) in
the UK to enhance public health security. Managed by the NIHR Clinical Research
Network, the mPower clinical trial will assess the effectiveness of an mRNA
mpox vaccine. Although public health measures have mitigated the spread of mpox
in the UK, the virus continues to pose a global threat, with only one licensed
vaccine for mpox available in Europe.
- In
August 2023, the UK Health Security Agency (UKHSA) sought to strengthen its
public health response to mpox by initiating a new study focused on
understanding asymptomatic transmission of the disease. Previous research has
indicated that individuals can contract mpox without exhibiting symptoms. The
PRIME study aims to expand on this research by determining the prevalence of
asymptomatic transmission. The government is encouraging individuals over 18
who have had close sexual contact with someone infected with mpox to participate
in the study, with a goal of recruiting up to 2,000 participants.
- According
to data published by gov.uk in 2024, the Vaccine Development and Evaluation
Centre (VDEC) played a key role in developing and evaluating new vaccines and
therapeutics. During the 2022 global mpox outbreak, VDEC rapidly developed an
immunoassay to assess serological markers in individuals vaccinated against
smallpox and those infected with mpox.
Key Market Players
- Chimerix UK
Limited
- SIGA
Technologies, Inc.
- Emergent
BioSolutions UK Ltd.
- Bavarian
Nordic A/S
- Mylan
N.V.
- Olon
S.p.A.
- Teva
UK Limited
|
By
Treatment
|
By
End User
|
By
Region
|
- Smallpox
Vaccine
- Antivirals
- Vaccinia
Immune Globulin (VIG)
|
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
|
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire
& Humberside
- East
Midlands
|
Report Scope
In this report, the United Kingdom Monkeypox
Therapeutics Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- United Kingdom Monkeypox Therapeutics Market, By Treatment:
o Smallpox Vaccine
o Antivirals
o Vaccinia Immune Globulin (VIG)
- United Kingdom Monkeypox Therapeutics Market, By End User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
- United Kingdom Monkeypox Therapeutics Market,
By Region:
o Scotland
o South-East
o London
o South-West
o East-Anglia
o Yorkshire & Humberside
o East Midlands
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United
Kingdom Monkeypox Therapeutics Market.
Available Customizations:
United Kingdom Monkeypox Therapeutics Market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
United Kingdom Monkeypox
Therapeutics Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]